|
is a covered service under the covered person's health |
benefit plan, but the health carrier has determined that |
the health care service is not covered because it does not |
meet the health carrier's requirements for medical |
necessity, appropriateness, health care setting, level of |
care, or effectiveness; |
(3) the covered person has exhausted the health |
carrier's internal grievance process as set forth in this |
Act; |
(4) for appeals relating to a determination based on |
treatment being experimental or investigational, the |
requested health care service or treatment that is the |
subject of the adverse determination or final adverse |
determination is a covered benefit under the covered |
person's health benefit plan except for the health |
carrier's determination that the service or treatment is |
experimental or investigational for a particular medical |
condition and is not explicitly listed as an excluded |
benefit under the covered person's health benefit plan with |
the health carrier and that the covered person's health |
care provider, who ordered or provided the services in |
question and who is licensed under the
Medical Practice Act |
of 1987 is a physician licensed to practice medicine in all |
its branches , has certified that one of the following |
situations is applicable: |
(A) standard health care services or treatments |
|
have not been effective in improving the condition of |
the covered person; |
(B) standard health care services or treatments |
are not medically appropriate for the covered person; |
(C) there is no available standard health care |
service or treatment covered by the health carrier that |
is more beneficial than the recommended or requested |
health care service or treatment;
|
(D) the health care service or treatment is likely |
to be more beneficial to the covered person, in the |
health care provider's opinion, than any available |
standard health care services or treatments; or |
(E) that scientifically valid studies using |
accepted protocols demonstrate that the health care |
service or treatment requested is likely to be more |
beneficial to the covered person than any available |
standard health care services or treatments; and |
(5) the covered person has provided all the information |
and forms required to process an external review, as |
specified in this Act. |
(c) Within one business day after completion of the |
preliminary review, the health carrier shall notify the covered |
person and, if applicable, the covered person's authorized |
representative in writing whether the request is complete and |
eligible for external review. If the request: |
(1) is not complete, the health carrier shall inform |
|
the covered person and, if applicable, the covered person's |
authorized representative in writing and include in the |
notice what information or materials are required by this |
Act to make the request complete; or |
(2) is not eligible for external review, the health |
carrier shall inform the covered person and, if applicable, |
the covered person's authorized representative in writing |
and include in the notice the reasons for its |
ineligibility.
|
The notice of initial determination of ineligibility shall |
include a statement informing the covered person and, if |
applicable, the covered person's authorized representative |
that a health carrier's initial determination that the external |
review request is ineligible for review may be appealed to the |
Director by filing a complaint with the Director. |
Notwithstanding a health carrier's initial determination |
that the request is ineligible for external review, the |
Director may determine that a request is eligible for external |
review and require that it be referred for external review. In |
making such determination, the Director's decision shall be in |
accordance with the terms of the covered person's health |
benefit plan and shall be subject to all applicable provisions |
of this Act. |
(d) Whenever a request is eligible for external review the |
health carrier shall, within 5 business days: |
(1) assign an independent review organization from the |
|
list of approved independent review organizations compiled |
and maintained by the Director; and |
(2) notify in writing the covered person and, if |
applicable, the covered person's authorized representative |
of the request's eligibility and acceptance for external |
review and the name of the independent review organization. |
The health carrier shall include in the notice provided to |
the covered person and, if applicable, the covered person's |
authorized representative a statement that the covered person |
or the covered person's authorized representative may, within 5 |
business days following the date of receipt of the notice |
provided pursuant to item (2) of this subsection (d), submit in |
writing to the assigned independent review organization |
additional information that the independent review |
organization shall consider when conducting the external |
review. The independent review organization is not required to, |
but may, accept and consider additional information submitted |
after 5 business days. |
(e) The assignment of an approved independent review |
organization to conduct an external review in accordance with |
this Section shall be made from those approved independent |
review organizations qualified to conduct external review as |
required by Sections 50 and 55 of this Act. |
(f) Upon assignment of an independent review organization, |
the health carrier or its designee utilization review |
organization shall, within 5 business days, provide to the |
|
assigned independent review organization the documents and any |
information considered in making the adverse determination or |
final adverse determination; in such cases, the following |
provisions shall apply: |
(1) Except as provided in item (2) of this subsection |
(f), failure by the health carrier or its utilization |
review organization to provide the documents and |
information within the specified time frame shall not delay |
the conduct of the external review. |
(2) If the health carrier or its utilization review |
organization fails to provide the documents and |
information within the specified time frame, the assigned |
independent review organization may terminate the external |
review and make a decision to reverse the adverse |
determination or final adverse determination. |
(3) Within one business day after making the decision |
to terminate the external review and make a decision to |
reverse the adverse determination or final adverse |
determination under item (2) of this subsection (f), the |
independent review organization shall notify the health |
carrier, the covered person and, if applicable, the covered |
person's authorized representative, of its decision to |
reverse the adverse determination. |
(g) Upon receipt of the information from the health carrier |
or its utilization review organization, the assigned |
independent review organization shall review all of the |
|
information and documents and any other information submitted |
in writing to the independent review organization by the |
covered person and the covered person's authorized |
representative. |
(h) Upon receipt of any information submitted by the |
covered person or the covered person's authorized |
representative, the independent review organization shall |
forward the information to the health carrier within 1 business |
day. |
(1) Upon receipt of the information, if any, the health |
carrier may reconsider its adverse determination or final |
adverse determination that is the subject of the external |
review.
|
(2) Reconsideration by the health carrier of its |
adverse determination or final adverse determination shall |
not delay or terminate the external review.
|
(3) The external review may only be terminated if the |
health carrier decides, upon completion of its |
reconsideration, to reverse its adverse determination or |
final adverse determination and provide coverage or |
payment for the health care service that is the subject of |
the adverse determination or final adverse determination. |
In such cases, the following provisions shall apply: |
(A) Within one business day after making the |
decision to reverse its adverse determination or final |
adverse determination, the health carrier shall notify |
|
the covered person and if applicable, the covered |
person's authorized representative, and the assigned |
independent review organization in writing of its |
decision. |
(B) Upon notice from the health carrier that the |
health carrier has made a decision to reverse its |
adverse determination or final adverse determination, |
the assigned independent review organization shall |
terminate the external review. |
(i) In addition to the documents and information provided |
by the health carrier or its utilization review organization |
and the covered person and the covered person's authorized |
representative, if any, the independent review organization, |
to the extent the information or documents are available and |
the independent review organization considers them |
appropriate, shall consider the following in reaching a |
decision: |
(1) the covered person's pertinent medical records; |
(2) the covered person's health care provider's |
recommendation; |
(3) consulting reports from appropriate health care |
providers and other documents submitted by the health |
carrier, the covered person, the covered person's |
authorized representative, or the covered person's |
treating provider; |
(4) the terms of coverage under the covered person's |
|
health benefit plan with the health carrier to ensure that |
the independent review organization's decision is not |
contrary to the terms of coverage under the covered |
person's health benefit plan with the health carrier; |
(5) the most appropriate practice guidelines, which |
shall include applicable evidence-based standards and may |
include any other practice guidelines developed by the |
federal government, national or professional medical |
societies, boards, and associations; |
(6) any applicable clinical review criteria developed |
and used by the health carrier or its designee utilization |
review organization; and |
(7) the opinion of the independent review |
organization's clinical reviewer or reviewers after |
considering items (1) through (6) of this subsection (i) to |
the extent the information or documents are available and |
the clinical reviewer or reviewers considers the |
information or documents appropriate; and |
(8) for a denial of coverage based on a determination |
that the health care service or treatment recommended or |
requested is experimental or investigational, whether and |
to what extent: |
(A) the recommended or requested health care |
service or treatment has been approved by the federal |
Food and Drug Administration, if applicable, for the |
condition; |
|
(B) medical or scientific evidence or |
evidence-based standards demonstrate that the expected |
benefits of the recommended or requested health care |
service or treatment is more likely than not to be |
beneficial to the covered person than any available |
standard health care service or treatment and the |
adverse risks of the recommended or requested health |
care service or treatment would not be substantially |
increased over those of available standard health care |
services or treatments; or |
(C) the terms of coverage under the covered |
person's health benefit plan with the health carrier to |
ensure that the health care service or treatment that |
is the subject of the opinion is experimental or |
investigational would otherwise be covered under the |
terms of coverage of the covered person's health |
benefit plan with the health carrier. |
(j) Within 5 days after the date of receipt of all |
necessary information, the assigned independent review |
organization shall provide written notice of its decision to |
uphold or reverse the adverse determination or the final |
adverse determination to the health carrier, the covered person |
and, if applicable, the covered person's authorized |
representative. In reaching a decision, the assigned |
independent review organization is not bound by any claim |
determinations reached prior to the submission of information |
|
to the independent review organization. In such cases, the |
following provisions shall apply: |
(1) The independent review organization shall include |
in the notice: |
(A) a general description of the reason for the |
request for external review; |
(B) the date the independent review organization |
received the assignment from the health carrier to |
conduct the external review; |
(C) the time period during which the external |
review was conducted; |
(D) references to the evidence or documentation, |
including the evidence-based standards, considered in |
reaching its decision; |
(E) the date of its decision; and |
(F) the principal reason or reasons for its |
decision, including what applicable, if any, |
evidence-based standards that were a basis for its |
decision.
|
(2) For reviews of experimental or investigational |
treatments, the notice shall include the following |
information: |
(A) a description of the covered person's medical |
condition; |
(B) a description of the indicators relevant to |
whether there is sufficient evidence to demonstrate |
|
that the recommended or requested health care service |
or treatment is more likely than not to be more |
beneficial to the covered person than any available |
standard health care services or treatments and the |
adverse risks of the recommended or requested health |
care service or treatment would not be substantially |
increased over those of available standard health care |
services or treatments; |
(C) a description and analysis of any medical or |
scientific evidence considered in reaching the |
opinion; |
(D) a description and analysis of any |
evidence-based standards; |
(E) whether the recommended or requested health |
care service or treatment has been approved by the |
federal Food and Drug Administration, for the |
condition; |
(F) whether medical or scientific evidence or |
evidence-based standards demonstrate that the expected |
benefits of the recommended or requested health care |
service or treatment is more likely than not to be more |
beneficial to the covered person than any available |
standard health care service or treatment and the |
adverse risks of the recommended or requested health |
care service or treatment would not be substantially |
increased over those of available standard health care |
|
services or treatments; and |
(G) the written opinion of the clinical reviewer, |
including the reviewer's recommendation as to whether |
the recommended or requested health care service or |
treatment should be covered and the rationale for the |
reviewer's recommendation. |
(3) In reaching a decision, the assigned independent |
review organization is not bound by any decisions or |
conclusions reached during the health carrier's |
utilization review process or the health carrier's |
internal grievance or appeals process. |
(4) Upon receipt of a notice of a decision reversing |
the adverse determination or final adverse determination, |
the health carrier immediately shall approve the coverage |
that was the subject of the adverse determination or final |
adverse determination.
|
(Source: P.A. 96-857, eff. 7-1-10.)
|
Section 95. No acceleration or delay. Where this Act makes |
changes in a statute that is represented in this Act by text |
that is not yet or no longer in effect (for example, a Section |
represented by multiple versions), the use of that text does |
not accelerate or delay the taking effect of (i) the changes |
made by this Act or (ii) provisions derived from any other |
Public Act.
|